Xiaofan Yuan

Dr. Xiaofan Yuan

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Journal of Lipid Research
Verified
Journal Article
Open access
XYXiaofan Yuan
Xiaofan Yuan
HXHongmei Xiao
Hongmei Xiao
QHQingzhe Hu
Qingzhe Hu
GSGuanru Shen
Guanru Shen
XQXinyue Qin
Xinyue Qin
Repulsive guidance molecule a (RGMa) is a glycosylphosphatidylinositol-anchored glycoprotein that has been demonstrated to influence inflammatory-related diseases in addition to regulating neuronal differentiation and survival during brain development. However, any function or mechanism of RGMa in dedifferentiation of contractile vascular smooth muscle cells (VSMCs) during inflammatory-related atherosclerosis is poorly understood. In the current study, we found that RGMa is expressed in VSMCs-derived macrophage-like cells from the fibrous cap of type V atherosclerotic plaques and the neointima of ligated carotid artery in ApoE−/− mice. We determined levels of RGMa mRNA and protein increased in oxidized LDL (ox-LDL)-induced VSMCs. Knockdown of RGMa, both in vivo and in vitro, inhibited the dedifferentiation of ox-LDL-induced VSMCs and their ability to proliferate and migrate, reduced the thickness of the neointima after ligation of the left common carotid artery in ApoE−/− mice. Additionally, we show RGMa promoted the dedifferentiation of VSMCs via enhancement of the role of transcription factor Slug. Slug knockdown reversed the dedifferentiation of ox-LDL-induced VSMCs promoted by RGMa overexpression. Thus, inhibition of RGMa may constitute a therapeutic strategy for atherosclerotic plaques prone to rupture and restenosis following mechanical injury.

18 June 2025 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
CJChuan Jiang
Chuan Jiang
JYJiasen Ye
Jiasen Ye
JHJie Huang
Jie Huang
YGYang Gao
Yang Gao
HCHong Chen
Hong Chen
XYXiaofan Yuan
Xiaofan Yuan
In-stent restenosis (ISR) remains a significant public health challenge globally, as millions of stents are implanted annually. Elucidating the mechanisms underlying ISR is essential for developing effective preventive and therapeutic strategies. In this study, we identified SOX9, a transcription factor, as a key factor involved in the pathogenesis of ISR. Morphological and histological analyses of human carotid atherosclerotic plaques revealed high expression of SOX9 at the interface between the fibrous cap (FC)—predominantly composed of α-smooth muscle actin (α-SMA)-positive vascular smooth muscle cells (VSMCs)—and the lipid-rich necrotic core (LRNC), enriched with CD68-positive macrophages. This region is characterized by a high frequency of phenotypic transformation of VSMCs. Using a carotid artery balloon injury model, we observed high expression of SOX9 in the neointima, and SOX9 knockdown significantly attenuated intimal hyperplasia. In vitro, SOX9 knockdown in primary VSMCs suppressed platelet-derived growth factor-BB (PDGF-BB)-induced phenotypic transformation, proliferation, and migration. Further studies using CUT&Tag analysis indicated that PDGF-BB promotes the AMPK signaling pathway, leading to the nuclear translocation of SOX9. A dual-luciferase reporter assay revealed that SOX9 directly binds to the motif of the signal transducer and activator of transcription 3 (STAT3) promoter, thereby enhancing the phenotypic transformation of VSMCs. This study uncovered a novel molecular mechanism in which AMPK-mediated SOX9 activation facilitates its interaction with STAT3 to regulate the transformation, proliferation, and migration of VSMCs. These findings suggest that targeting the SOX9–STAT3 axis can serve as a promising therapeutic strategy for the prevention and treatment of ISR.

18 April 2024 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
XYXiaofan Yuan
Xiaofan Yuan
CJChuan Jiang
Chuan Jiang
YXYuzhou Xue
Yuzhou Xue
FGFuqiang Guo
Fuqiang Guo
MLMinghao Luo
Minghao Luo
HCHong Chen
Hong Chen

9 June 2026 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
JHJie Huang
Jie Huang
JWJia Wang
Jia Wang
HCHong Chen
Hong Chen
FGFuqiang Guo
Fuqiang Guo
XYXiaofan Yuan
Xiaofan Yuan
Interferon regulatory factors (IRFs) constitute a family of transcription factors that orchestrate innate and adaptive immune responses, metabolic regulation, and cellular homeostasis. Emerging evidence demonstrates that IRF1–IRF9 play central immunometabolic roles in the formation, progression, and destabilization of atherosclerotic lesions. Pro-inflammatory IRFs, particularly IRF1, IRF3, IRF5, and IRF7, promote endothelial activation, M1 macrophage polarization, pyroptosis, impaired efferocytosis, and maladaptive phenotypic transformation of vascular smooth muscle cells (VSMCs), thereby amplifying vascular inflammation and leading to plaque vulnerability. In contrast, IRF2 and IRF4 exhibit anti-inflammatory and immunoregulatory properties, restraining excessive interferon signaling, supporting M2 macrophage polarization, and maintaining Treg/Th2 homeostasis. IRF8 and IRF9 display highly context- and cell-specific functions, integrating Dendritic cells (DCs) antigen presentation, T-cell activation, and VSMC remodeling with systemic metabolic cues. Therapeutically, both direct and indirect targeting strategies for IRFs are emerging, including small-molecule inhibitors, epigenetic modulators, upstream pathway blockade, microRNA-based interventions, and nutraceutical approaches. However, given their essential roles in antiviral immunity, future translational efforts must prioritize cell-and tissue-specific IRF modulation strategies to prevent systemic immunosuppression. Collectively, IRFs represent a convergent molecular axis linking immune activation, metabolic disturbance, and hemodynamic stress. A deeper understanding of IRF signaling networks, guided by single-cell multi-omics, genetic stratification, and precision delivery systems, may enable the development of immune-metabolic therapies to address residual inflammatory risk in atherosclerotic cardiovascular diseases.

4 March 2022 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
XYXiaofan Yuan
Xiaofan Yuan
GSGuanru Shen
Guanru Shen
QHQingzhe Hu
Qingzhe Hu
HXHongmei Xiao
Hongmei Xiao
XQXinyue Qin
Xinyue Qin

13 July 2023 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
XYXiaofan Yuan
Xiaofan Yuan
GSGuanru Shen
Guanru Shen
HXHongmei Xiao
Hongmei Xiao
ZWZijie Wang
Zijie Wang
YMYue Ma
Yue Ma
XQXinyue Qin
Xinyue Qin